Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRI97M
|
|||
| Drug Name |
MGD014
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Phase 1 | [1] | |
| Company |
MacroGenics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) | Target Info | Inhibitor | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03570918) MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of MacroGenics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.